AgomAb Therapeutics NV (AGMB) stock
AGMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$5.92−0.05 (-0.84%)
Close on Nov 17, 2026Market cap $148.00KP/E –Yield –
AgomAb Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
For fiscal 2025 it was -€51.74M.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -€51.74M | – |
| FY2024 | Dec 31, 2024 | -€46.83M | – |
| FY2023 | Dec 31, 2023 | -€24.59M | – |
See a number that looks wrong?